Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications
Nutrients · 2025
DOI: 10.3390/nu17111853 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2025. Verfasst von Chen Mei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China. Hauptthemen laut MEDLINE: Quercetin, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Academy of Agriculture and Forestry Sciences Special Science and Technology Research Project for Innovation Capacity Building, the Reform and Development Project of Beijing Academy of Agricultural and Forestry Sciences, Project of the Beijing Academy of Agriculture and Forestry Sciences Special Science and Technology Research Project for Innovation Capacity Building.
Abstract (Originalsprache)
Isorhamnetin (ISO) is a natural flavonoid compound that has become a main research topic in recent years due to its multitargeted antitumor properties. In this paper, we systematically review the molecular basis of the inhibition of malignant tumors by ISO, including through the regulation of the cell cycle, PI3K/AKT/mTOR pathway, MAPK pathway, apoptosis/autophagy-related pathways, and the tumor microenvironment. We also explore its synergistic effects with chemotherapy/targeted therapies and its potential for clinical translation. Experimental studies have shown that ISO can not only directly inhibit tumor proliferation by inducing tumor cell cycle arrest, mitochondria-dependent apoptosis, and endoplasmic reticulum stress, but also enhance antitumor immune responses by regulating the immune microenvironment. Pharmacokinetic studies have shown that novel delivery systems, such as nano-formulations, significantly enhance the bioavailability of ISO. Notably, ISO has demonstrated unique advantages in attenuating the nephrotoxicity of chemotherapeutic agents, protecting normal cells, and reversing tumor resistance. However, the optimal dosing regimen, dose–effect relationship, and cross-species applicability need to be further validated by large-scale preclinical animal experiments and clinical trials. This paper provides a theoretical basis for the development and application of ISO for the treatment of malignant tumors and highlights its potential value in animal models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China.
- College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
- Beijing General Animal Husbandry Station, Beijing 100107, China.
- Laboratory for Clinical Medicine, Capital Medical University, Beijing 100010, China.
ORCID-Profile: Chen Mei, Zhenyi Liu, Yan Zhi
Förderung
- Beijing Academy of Agriculture and Forestry Sciences Special Science and Technology Research Project for Innovation Capacity Building
- the Reform and Development Project of Beijing Academy of Agricultural and Forestry Sciences
- Project of the Beijing Academy of Agriculture and Forestry Sciences Special Science and Technology Research Project for Innovation Capacity Building
- Reform and Development Project of Beijing Academy of Agricultural and Forestry Sciences
Zitieren
APA
Mei, C., Liu, Y., Lyu, X., Jiang, Z., Liu, Z., Zhi, Y., Xu, X., & Wang, H. (2025). Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications. Nutrients. https://doi.org/10.3390/nu17111853
Vancouver
Mei C, Liu Y, Lyu X, Jiang Z, Liu Z, Zhi Y, et al. Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications. Nutrients. 2025. doi:10.3390/nu17111853
BibTeX
@article{Mei2025,
author = {Mei, Chen and Liu, Ying and Lyu, Xueze and Jiang, Zhaoling and Liu, Zhenyi and Zhi, Yan and Xu, Xiaolong and Wang, Hongjun},
title = {Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17111853}
}
EUVIMED